Navigation Links
Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
Date:3/4/2009

for REOLYSIN to commercial scale. Financial and Intellectual Property ----------------------------------- - In December, Oncolytics closed a public offering that added a net $3.4 million to Oncolytics' financial reserves, bringing the total to $13.3 million in cash and equivalents at December 31, 2008; and, - Secured five U.S. and three Canadian patents in 2008. Currently more than 200 patents have been issued worldwide, including 31 US and 9 Canadian. "We are greatly encouraged by the clinical results we are seeing in our clinical trials, and by the continued enthusiasm displayed by our collaborators," said Dr. Thompson. "We look forward to taking REOLYSIN into to the final stages of development in 2009." Oncolytics Biotech Inc. CONSOLIDATED BALANCE SHEETS As at December 31 2008 2007 $ $ ------------------------------------------------------------------------- ASSETS Current Cash and cash equivalents 7,429,895 6,715,096 Short-term investments 5,846,634 18,498,733 Accounts receivable 86,322 80,085 Prepaid expenses 179,668 260,300 ------------------------------------------------------------------------- 13,542,519 25,554,214 Property and equipment 263,926 201,103 Intellectual property 180,750 542,250 ------------------------------------------------------------------------- 13,987,195 26,297,567 ---------------------
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
(Date:7/24/2014)... team led by group leader Yung-Eun Sung has ... synthesize sulfur-doped and nitrogen-doped graphenes which can be ... and fuel cells. Yung-Eun Sung is both a ... at Institute for Basic Science* (IBS) and a ... achievement has great significance with regards to the ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... Culture Market 2014-2018" report to their offering.  ... culture is the in vitro growth of plant or ... studies, and biopharmaceutical production. Cell culture is a crucial ... instruments and cell culture consumables are necessary for the ...
(Date:7/24/2014)...  CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical ... for the prevention and treatment of cardiorenal and ... July 18, 2014 from the NYSE MKT LLC ... plan to regain compliance with continued listing standards ... is continuing the Company,s listing and has granted ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... Schering-Plough Assumes Exclusive Worldwide Marketing Rights for ... N.J., May 19 Schering-Plough Corporation (NYSE: ... to its global collaboration with Novartis for ... therapies for the treatment of asthma and ...
... May 18 Solvay Pharmaceuticals announces it ... a company specialized in enabling and accelerating global ... China. Through this agreement, Solvay Pharmaceuticals will gain ... specifically on compounds in the cardiovascular area. ...
... Entire ALS Community to Join a Nationwide Network of ... ALS Therapy Development Institute (ALS TDI) announced its ... designed to increase the awareness and understanding of ALS ... To accomplish its goal, the campaign brings together three ...
Cached Biology Technology:Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 2Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 3Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 4Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 5Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 6Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 7Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 8Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China 2Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China 3Campaign to Increase the Awareness and Understanding of Lou Gehrig's Disease Reaches 22 U.S. States 2Campaign to Increase the Awareness and Understanding of Lou Gehrig's Disease Reaches 22 U.S. States 3
(Date:7/24/2014)... new study has identified two factors that characterize ... the production of highly qualified physics teachers. Specifically, ... champion physics teacher education in combination with institutional ... remain viable. Science, Technology, Engineering and Math (STEM) ... the study points the way for institutions seeking ...
(Date:7/24/2014)... Some sticky research out of York University shows ... species of toxic grass fungus: moose saliva (yes moose ... Letters , "Ungulate saliva inhibits a grassendophyte mutualism" shows ... fescue grass (which hosts a fungus called epichlo festucae ... growth and less toxicity. , "Plants have evolved defense ...
(Date:7/24/2014)... at Albert Einstein College of Medicine of ... J. Fox Foundation for Parkinson,s Research to translate a ... This drug discovery project will test chemical compounds on ... a drug that acts on an underlying cause of ... help many people manage their symptoms, we are eager ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Moose drool inhibits growth of toxic fungus: York U research 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3
... are elementary building blocks of life. They often perform ... to fold into three-dimensional structures. Misfolding of proteins leads ... strategies did nature develop over the course of evolution ... chemist Dr. Frauke Grter (Heidelberg Institute for Theoretical Studies) ...
... January 31, 2013 -- Deborah E. Wiley, Chair of ... JWa & JWb), announced today that the twelfth annual ... Dr. Michael Young, Rockefeller University, Dr. Jeffrey Hall, Brandeis ... The Wiley Prize is being awarded to Dr. Young, ...
... N.C. In the last decade, a new strain of ... everyone at risk of contracting the dangerous bacterial infection. This ... a chunk of genes not shared by any other strains, ... the bacteria to survive and persist in the community. ...
Cached Biology News:Protein origami: Quick folders are the best 2Protein origami: Quick folders are the best 312th annual Wiley Prize in Biomedical Sciences awarded 212th annual Wiley Prize in Biomedical Sciences awarded 3UNC study may lead to treatments that are effective against all MRSA strains 2
... ShortCut RNase III, used with its manganese-containing ... a heterogeneous mix of short (1825 bp) ... in mammalian cells. 1.3 units (1 l) ... convert 1 g of dsRNA into siRNA ...
EZ-Tn5™ Transposase is designed for use with our pMOD™ series of vectors as well as any EZ-Tn5™ transposon system....
HIV Reverse Transcriptase provides an excellent target for evaluating antiviral agents or catalyzing error prone synthesis on RNA and DNA templates....
OmniSlide thermal Cycler for slide applications. 20 slide capacity. Humidity Chamber. Slide Rack can be transferred directly to Wash Module to avoid handling individual slides....
Biology Products: